Onco Actu du 29 mai 2015

	1. Biologie
Researchers uncover how breast cancer can spread to bone [Cancer Research UK] Building on previous findings, the scientists, based at the University of Sheffield, found that when breast cancer cells release a chemical called lysyl oxidase (LOX), it makes bone tissue a fertile ground for cancer cells to spread or metastasis.
Sleeping cancer cells can 'wake up' decades later [BBC News] The study, published in the journal Leukemia, found that the cancer cells which 'woke up' in the patient after a period of two decades were similar to a group of cancer cells that pre-dated the original bout of the disease.
	3.1 Tabac
Approaches for Controlling Illicit Tobacco Trade — Nine Countries and the European Union [MMWR-CDC] Research suggests that the revenue gains from eliminating illicit tobacco trade globally would exceed $31 billion, and might help prevent more than 160,000 tobacco-related deaths per year from 2030 onwards.
	4. Dépistage, diagnostic et pronostic
Engineered bacteria detect cancer and diabetes in urine [Science] What's more, Bhatia and her colleagues report in the current issue of Science Translational Medicine this week, while conventional imaging techniques struggle to detect liver tumors smaller than 1 square centimeter, this approach was able to flag tumors as small as 1 square millimeter.
Bacteria sensors 'detect diabetes and cancer' [BBC News] Scientists can transform bacteria into tiny living computers capable of detecting diabetes and cancer, early studies suggest.
	5.2.1 Pharma - Partenariats
Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab) [Merck] NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in over 700 peer-reviewed publications.
AstraZeneca and Lilly to test new cancer drug combination [Reuters] AstraZeneca’s experimental anti-PD-L1 immunotherapy drug MEDI4736 will be tested alongside Lilly's approved medicine Cyramza, or ramucirumab.
	5.2.2 Pharma - Fusions & Acquisitions
Buzz: Cellectis could be in line for a $1.6B Pfizer buyout [FierceBiotech] The Financial Times is citing two people close to the situation who say the French biotech is in the early stages of negotiations.
	5.3 Traitements - FDA, EMA,...
European Medicines Agency Recommends Granting a Marketing Authorisation for Generic Bortezomib [ESMO] Bortezomib Accord is a generic of Velcade which has been authorised in the EU since April 2004. Studies have demonstrated the satisfactory quality of Bortezomib Accord. Since Bortezomib Accord is administered intravenously and is 100% bioavailable, a bioequivalence study versus the reference product Velcade was not required.
	5.5.1 ASCO (général)
Two Types of Risk [In the Pipeline] How do you differentiate your tyrosine kinase approach, or immuno-oncology approach, from everyone else's? That's a particularly fraught question in oncology, where the animal models are so nonpredictive and questions like this get settled in the clinic.
ASCO 2015: Abstract Thoughts On Cancer And Competition [LifeSciVC] While it’s hard to know if there will be any positive or negative surprises this year, at least until the weekend is over, a quick “Friday fun” data analysis of the nearly 5000 abstracts reveals the rather narrow focus of the community’s attention (though I’m likely contributing more to noise than signal).
	5.5.1.1 ASCO (général) - Industriels
Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting [Seattle Genetics] Seattle Genetics is evaluating its ADC technology broadly through ADCETRIS, proprietary pipeline and collaborator programs.
Lilly to Present CYRAMZA® (ramucirumab) Data at 2015 ASCO Annual Meeting [Lilly] "In just over a year, CYRAMZA received four full FDA approvals in advanced or metastatic forms of three of the world's most common and deadly cancers - gastric, non-small cell lung, and colorectal," said Richard Gaynor, M.D., senior vice president, product development and medical affairs for Lilly Oncology.
Puma Bio (PBYI) Restricting Access to Breast Cancer Event at ASCO 2015 [TheStreet] Restricting access to a corporate event might not be such a big deal if not for Puma's penchant for selectively disclosing important information to people deemed friendly to the company.
New drugs from Bristol, Merck at forefront of cancer meeting [Reuters] Other drugmakers working on similar treatments include Roche Holding AG, AstraZeneca Plc and Pfizer Inc. Many industry experts expect the entire class will eventually generate billions of dollars in annual sales, particularly if proven effective against other forms of cancer.
	5.5.4 ASCO (immunothérapie)
ASCO Immunotherapy Preview: These Cancer-Killing Viruses May Save Lives [Forbes] Turning the dream of virotherapy into reality has not been easy, but this year, the field got a huge boost from the world’s largest biotech company, Amgen.
ASCO 2015: What to Watch in Immunotherapy [CRI] Because so much new information about immunotherapy is likely to be unveiled—including the results of clinical trials that have a direct bearing on patients—I have prepared a summary of what I consider to be the top areas to watch.
	5.5.8 ASCO (poumon)
PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting [Lilly] PROCLAIM was a randomized, Phase III superiority study of patients with locally-advanced, nonsquamous non-small cell lung cancer (NSCLC), which evaluated Lilly's ALIMTA® (pemetrexed for injection), in combination with cisplatin with concurrent radiation followed by maintenance ALIMTA in comparison with etoposide and cisplatin plus concurrent radiation, followed by consolidation chemotherapy of the oncologist's choice.
	5.6 ESMO
Challenges Ahead for European Clinical Trials [ESMO] Although still work in progress, the new EU Clinical Trials Regulation is definitely an opportunity to facilitate clinical cancer research in Europe and reduce some of the burdens that have proven so costly in the past.
	6.1 Observation
New cancer cases rise globally, but death rates are declining in many countries [Institute for Health Metrics and Evaluation] Prostate cancer and breast cancer have increased significantly since 1990, and cancer poses a special challenge in developing countries where access to screening and costly treatment is rare.
	6.11 Patients
A-level student died from stomach cancer after doctors dismissed her weightloss [The Telegraph] Despite the teenager's mother begging doctors to pay attention to her daughter's symptoms, one doctor told her, "I know what you 18-year-olds are like for wanting to look like stick insects".
Well: Smuggling a Beer for My Hospital Patient [NY Times] I told the medical student I was working with that we were going on a field trip — to the liquor store. “Won’t we get in trouble?” he asked. I hoped not. But I had promised my patient a beer when it was all done, and that was a promise I could keep.
	6.6 Publications
Problems behind chocolate study “fooling millions” run much deeper than just a prank/spoof/sting [HealthNewsReview] Science journalist John Bohannon has done it again – providing another example of how easy it is to get slipshod studies published, and now, how easy it is to get naive news coverage of a slipshod study.
Speaking of wrong, so is everything about and in this piece on science reporting [The Incidental Economist] It’s an amazing read, and it’s certainly captivating. It’s also shockingly unethical.
Should the chocolate-diet sting study be retracted? And why the coverage doesn't surprise a news watchdog [Retraction Watch] The health and science news food chain that feeds the consuming public is contaminated by different players at different stages along the way. The problem is much worse than a publishing prank that fools millions. It’s a credibility crisis for science and for journalism. And consumers at the end of the food chain will be – indeed, already are – poisoned.
Chocolate-diet study publisher claims paper was actually rejected, only live “for some hours." Email, however, says...[Retraction Watch] This isn’t Bohannon’s first sting operation — in 2013, he found that fewer than half of publishers of open access journals rejected deeply “flawed” papers which he assembled.
	6.7 DMP, Big Data & applis
Open data could save the NHS hundreds of millions, says top UK scientist [The Guardian] "There’s lots of data in the health service that is not about personal patient data at all that would be hugely useful to just have available as machine-readable data for apps to use.”
	6.7.3 DMP
Creative Minds: Building a Better Electronic Health Record [NIH Director's Blog] Is 5 too few and 40 too many? That’s one of many questions that researcher David Chan is asking about the clinical reminders embedded into those electronic health record (EHR) systems increasingly used at your doctor’s office or local hospital. Electronic reminders, which are similar to the popups that appear when installing software on your computer, flag items for healthcare professionals to consider when they are seeing patients.